Deepika Pakianathan, a director at Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a pharmaceutical company specializing in the development of treatments for cancer, has recently sold a significant amount of company stock. The transactions, which occurred on multiple dates, resulted in the sale of shares worth over $880,000.
The sales were executed in a series of transactions at varying prices. On May 31, 2024, Pakianathan sold 202,418 shares at an average price of $0.954 per share and another 1,976 shares at the same price. The following day, on June 3, a total of 357,256 shares were sold at an average price of $1.0007 per share, along with an additional 3,488 shares at that average price. The sales continued on June 4, with 337,742 shares going for an average price of $0.9521 per share, and 3,298 shares sold at the same average price.
The sales occurred within a price range of $0.9521 to $1.0007 per share. It's worth noting that these shares were sold in multiple transactions at prices that varied within the stated ranges. Pakianathan has agreed to provide full information regarding the number of shares sold at each separate price within the range upon request.
Deepika Pakianathan's transactions were reported in a Form 4 filing with the Securities and Exchange Commission. According to the footnotes in the document, the shares sold were indirectly owned through Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P., where Pakianathan is a managing member. While she shares voting and investment power over the securities held by these entities, she disclaims beneficial ownership of the securities, except to the extent of her proportionate pecuniary interest therein.
Following these transactions, Pakianathan's indirect ownership in Karyopharm Therapeutics Inc. has been adjusted, but the exact details of her remaining stake have not been disclosed in the filing. Investors and followers of Karyopharm will likely keep an eye on these developments as part of their ongoing assessment of the company's stock performance and insider activity.
InvestingPro Insights
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has recently witnessed significant insider transactions, with director Deepika Pakianathan selling over $880,000 worth of company stock. To provide investors with a broader understanding of the company's financial health, here are some key metrics and insights from InvestingPro.
InvestingPro Data shows a market capitalization of $115.39 million USD, reflecting the company's size in the pharmaceutical industry. Despite the challenges, KPTI boasts an impressive gross profit margin of 93.89% for the last twelve months as of Q1 2024, indicating efficient management of production costs relative to sales.
However, KPTI is facing some financial headwinds. The company's P/E Ratio stands at -0.75, and the adjusted P/E Ratio for the last twelve months as of Q1 2024 is -0.84, suggesting that investors are currently not expecting earnings growth. Additionally, the company experienced a revenue decline of 5.16% over the last twelve months as of Q1 2024, with a quarterly revenue drop of 14.4% in Q1 2024, which could be a concern for potential investors.
InvestingPro Tips highlight that Karyopharm operates with a significant debt burden and is quickly burning through cash. Moreover, analysts do not anticipate the company will be profitable this year, and the valuation implies a poor free cash flow yield. These factors are critical for investors to consider, especially in light of the recent insider selling activity.
For a deeper analysis, there are 8 additional InvestingPro Tips available for KPTI at https://www.investing.com/pro/KPTI. These insights can further aid investors in making informed decisions. Remember to use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enriching your investment strategy with comprehensive data and expert analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.